Protocol I6T-MC-AMAX A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients with Crohn’xxs DiseaseVIVID 2. Lilly, Sub-Investigator - Faz 3